Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting

o BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB- 509 clinical trials, whether the SB
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:7/7/2015)... , July 7, 2015  Essentialis, a venture-backed company ... for the treatment of orphan neurobehavioral and metabolic diseases, today ... CSO, will present a corporate update at the Cantor Fitzgerald ... Date: Wednesday, July 8, 2015 Time: 8:00 ... About Essentialis, Inc. Essentialis ...
(Date:7/7/2015)... -- Oasmia Pharmaceutical AB, a developer of ... oncology, has filed a registration statement on Form F-1/A ... the proposed public offering of ordinary stock and listing ... Depositary Shares, representing ordinary shares, to be offered, and ... been determined. An Investor Roadshow will be conducted in ...
(Date:7/7/2015)... , July 7, 2015  Monopar Therapeutics LLC, an ... announced that its co-founder and CEO, Chandler D. ... Education U.K. Alumni Entrepreneurial Award. The British Council selected ... , India , and ... achievements made by entrepreneurs who have leveraged their U.K. ...
Breaking Medicine Technology:Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3
... 2012 Current research ethics focuses on protecting study ... and McGill University, these efforts fail to prevent problems ... (Logo:  http://photos.prnewswire.com/prnh/20020422/CMULOGO ) Published in ... and McGill,s Jonathan Kimmelman and Benjamin ...
... Ind., May 3, 2012 Hill-Rom Holdings, Inc. (NYSE: ... a management presentation at the Bank of America Merrill ... May 16, 2012, at 1:40 p.m. EDT. ... via the internet link at  http://ir.hill-rom.com/events.cfm or access ...
Cached Medicine Technology:Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices 2Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices 3
(Date:7/7/2015)... ... 07, 2015 , ... On Saturday, May 16th, 2015, the Manistee, MI chapter ... Country Club. Best Drug Rehabilitation staff members were delighted to join in for this ... International, the parent of the Manistee Kiwanis Club, is a global organization that works ...
(Date:7/7/2015)... Antonio, TX (PRWEB) , ... July 07, 2015 , ... ... has once again teamed up with Soldiers’ Angels and announced a new charity campaign ... is the motivation and mission of Soldiers’ Angels, which was created especially to care ...
(Date:7/7/2015)... ... July 07, 2015 , ... Office ... the company’s new Chief Financial Officer, effective July 6th, 2015. Ellen joins Office ... ranging from a multi-billion dollar, global chemical company to early and growth-stage technology ...
(Date:7/7/2015)... MO (PRWEB) , ... July 07, 2015 , ... ... liability law announce the launch of their new website, the Invokana Ketoacidosis ... Invokana FDA warning*, and serves as a resource for persons wishing to learn ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... they have been selected by the Department of Vermont Health Access to provide ... Management Information System (MMIS) and Integrated Contact Center System project. , Vermont is ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 2Health News:Clear Insurance Group and Nonprofit Soldiers’ Angels Initiate New Charity Campaign in San Antonio, TX to Provide Aid and Comfort for Veterans 3Health News:Office Practicum Announces new CFO 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2
... News) -- Eating fruits and vegetables may reduce the risk ... Austrailian researchers examined the diets of 918 colorectal cancer patients ... found that consumption of certain vegetables and fruits were associated ... distal colon -- that is, the upper and lower portions ...
... AMRI (NASDAQ: AMRI) today announced the receipt of a ... its Burlington, Massachusetts aseptic finish-and-fill facility, acquired in June ... a August 2010 warning letter and a June 2011 ... AMRI, once fully implemented, should adequately address the observations ...
... are likely to change their preferences for receiving emergency ... new findings. The study, which will be ... Amsterdam today (26 September 2011), suggests that different factors ... this will often go unnoticed by their healthcare provider. ...
... and face-to-face therapy sessions for couples improve the sex ... is the finding of a new study published early ... the American Cancer Society. The results suggest that couples ... beyond those experienced from medications such as erectile dysfunction ...
... cancer survivors and their partners experience improved sexual satisfaction ... The University of Texas MD Anderson Cancer Center. The ... , a journal of the American Cancer Society, revealed ... equally effective in improving sexual outcomes. Couples on a ...
... Sweden: Results from the longest-running trial comparing tamoxifen ... letrozole has withstood the test of time and ... the risk of death in post-menopausal women with ... Gelber told delegates at the 2011 European Multidisciplinary ...
Cached Medicine News:Health News:Broccoli, Cabbage, Other Veggies May Protect Against Colon Cancer 2Health News:Study shows decisions over life-sustaining treatment are likely to change 2Health News:Couples counseling helps improve the sex lives of prostate cancer survivors and their spouses 2Health News:Couples counseling improves sexual intimacy after prostate treatment 2Health News:Couples counseling improves sexual intimacy after prostate treatment 3Health News:Couples counseling improves sexual intimacy after prostate treatment 4Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: